TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35509104

Group type: EXPERIMENTAL
Intervention: ICH-LR2S2 risk score
Number of subjects: 70540

Group type: EXPERIMENTAL
Intervention: Machine learning methods such as XGboost
Number of subjects: 70540

Group type: EXPERIMENTAL
Intervention: ICH-LR2S2 risk score on external validation cohort
Number of subjects: 70540
Study: 33506357

Group type: EXPERIMENTAL
Intervention: Tart cherry juice (240 ml)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Tart cherry powdered capsule (480 mg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Tart cherry powdered capsule (480 mg, two capsules)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (not specified)
Number of subjects: 48
Study: 33140515

Group type: COMPARATOR
Intervention: Paclitaxel 80 mg/m2 weekly for 12 doses followed by FAC/FEC
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Eribulin 1.4 mg/m2 on days 1 and 8 of a 21-day cycle for 4 cycles followed by FAC/FEC
Number of subjects: 51

Group type: COMPARATOR
Intervention: Paclitaxel
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Eribulin
Number of subjects: 51
Study: 32134332

Group type: EXPERIMENTAL
Intervention: Bone‐anchored maxillary protraction (BAMP) not preceded by maxillary expansion
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Bone‐anchored maxillary protraction (BAMP) preceded by maxillary expansion
Number of subjects: 28
Study: 36384081

Group type: EXPERIMENTAL
Intervention: Low FODMAP diet (4 g/day)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Moderate FODMAP diet (23 g/day)
Number of subjects: 29
Study: 33504175

Group type: EXPERIMENTAL
Intervention: Behavioral Activation and Therapeutic Exposure for Grief
Number of subjects: 155

Group type: COMPARATOR
Intervention: Cognitive Therapy for Grief
Number of subjects: 155
Study: 32772701

Group type: EXPERIMENTAL
Intervention: Taping
Number of subjects: 31

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 31
Study: 36164681

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided selective nerve root block (SNRB)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Fluoroscopy-guided transforaminal epidural steroid injection (TFESI)
Number of subjects: 156
Study: 34147510

Group type: EXPERIMENTAL
Intervention: Negative social comparison
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Positive social comparison
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Negative general
Number of subjects: 254

Group type: COMPARATOR
Intervention: Neutral (control)
Number of subjects: 254
Study: 35858943

Group type: EXPERIMENTAL
Intervention: Nasal-spraying probiotics containing 5 billion Bacillus spores (LiveSpo Navax)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control-standard of care
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nasal-spraying probiotics (LiveSpo Navax)
Number of subjects: 40
Study: 32553279

Group type: COMPARATOR
Intervention: Low Dose (LD) group, 80 kV with a NI of 25 and iohexol (350 mg I/ml)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Further Low Dose (FLD) group, 80 kV with a NI of 30 and iomeprol (400 mg I/ml)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Low Dose (LD) group
Number of subjects: 180

Group type: COMPARATOR
Intervention: Further Low Dose (FLD) group
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Conventional Dose (CD) group, 100 kV with a NI of 25 and iohexol (350 mg I/ml)
Number of subjects: 180
Study: 35674733

Group type: EXPERIMENTAL
Intervention: Nano-curcumin (80 mg/day)
Number of subjects: 64
Study: 33655929

Group type: EXPERIMENTAL
Intervention: Internal Focus
Number of subjects: 12

Group type: COMPARATOR
Intervention: External Focus
Number of subjects: 12
Study: 32349138

Group type: EXPERIMENTAL
Intervention: Adenoma detection rate (ADR)
Number of subjects: 2889

Group type: EXPERIMENTAL
Intervention: Proximal serrated polyp detection rate (PSPDR)
Number of subjects: 2889

Group type: EXPERIMENTAL
Intervention: Sensitivity of optical diagnosis for adenomas
Number of subjects: 2889

Group type: EXPERIMENTAL
Intervention: Sensitivity of optical diagnosis for serrated polyps
Number of subjects: 2889

Group type: EXPERIMENTAL
Intervention: Correlation between ADR and sensitivity of optical diagnosis for adenomas
Number of subjects: 2889

Group type: EXPERIMENTAL
Intervention: Correlation between PSPDR and sensitivity of optical diagnosis for serrated polyps
Number of subjects: 2889
Study: 35894487

Group type: EXPERIMENTAL
Intervention: Paracervical block (PCB) with 1 minute wait
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Paracervical block (PCB) with 3 minutes wait
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Oral NSAIDs with 60 minutes wait
Number of subjects: 123
Study: 34610185

Group type: EXPERIMENTAL
Intervention: Chlorhexidine-impregnated dressing
Number of subjects: 307

Group type: COMPARATOR
Intervention: Standard dressing
Number of subjects: 307
Study: 32715442

Group type: EXPERIMENTAL
Intervention: Exemestane with UGT2B17 gene deletion
Number of subjects: 1752

Group type: COMPARATOR
Intervention: Placebo with UGT2B17 gene deletion
Number of subjects: 1752

Group type: EXPERIMENTAL
Intervention: Exemestane with lower metabolite ratio (poor detoxification)
Number of subjects: 1752
Study: 36408023

Group type: EXPERIMENTAL
Intervention: Sugemalimab plus chemotherapy (SC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus chemotherapy (PC)
Number of subjects: 0
Study: 33002839

Group type: EXPERIMENTAL
Intervention: BWS with visual feedback stimulation (Experimental VF+ group)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Advanced BWS gait training sessions without visual feedback (Experimental VF- group)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Conventional physical therapy (control group)
Number of subjects: 63
Study: 616357443

Group type: EXPERIMENTAL
Intervention: VesiGel 0.06% (40mg at 64mL gel; n=20)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: VesiGel 0.12% (80mg at 64mL gel; n=22)
Number of subjects: 64

Group type: COMPARATOR
Intervention: MMC 0.1% (40mg in 40mL water; n=23)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: VesiGel 0.06% for tumors <=1cm²
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: VesiGel 0.12% for tumors <=1cm²
Number of subjects: 64

Group type: COMPARATOR
Intervention: MMC 0.1% for tumors <=1cm²
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: VesiGel 0.06% for tumors >1cm²
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: VesiGel 0.12% for tumors >1cm²
Number of subjects: 64

Group type: COMPARATOR
Intervention: MMC 0.1% for tumors >1cm²
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: VesiGel 0.06% for patients with <=3 tumors
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: VesiGel 0.12% for patients with <=3 tumors
Number of subjects: 64

Group type: COMPARATOR
Intervention: MMC 0.1% for patients with <=3 tumors
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: VesiGel 0.06% for patients with >3 tumors
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: VesiGel 0.12% for patients with >3 tumors
Number of subjects: 64

Group type: COMPARATOR
Intervention: MMC 0.1% for patients with >3 tumors
Number of subjects: 64
Study: 35143041

Group type: EXPERIMENTAL
Intervention: Lung cancer screening (LCS)
Number of subjects: 843
Study: 33748882

Group type: EXPERIMENTAL
Intervention: Group A (factual explanation of MRI report)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Group B (reassured that MRI findings showed normal changes)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Clinical reporting method
Number of subjects: 44

Group type: COMPARATOR
Intervention: Routine MRI reporting
Number of subjects: 44
Study: 35368016

Group type: EXPERIMENTAL
Intervention: Kinesiology tape decompression/fan application with standard therapy
Number of subjects: 14

Group type: COMPARATOR
Intervention: Standard therapy with no kinesiology tape (Control)
Number of subjects: 14
Study: 34112732

Group type: EXPERIMENTAL
Intervention: 14-day group
Number of subjects: 90

Group type: COMPARATOR
Intervention: Bacterial load-guided group (BLGG)
Number of subjects: 90
Study: 32690830

Group type: EXPERIMENTAL
Intervention: 2% curcumin gel
Number of subjects: 25

Group type: COMPARATOR
Intervention: 0.2% chlorhexidine gel
Number of subjects: 25
Study: 34716525

Group type: EXPERIMENTAL
Intervention: Optimized group (lesions applied to the anterior/posterior carina and the ridge between the left atrial appendage and the left pulmonary vein, followed by continuous lesions)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sequential group (continuous circular lesions created counter-clockwise starting from the site of 6 o'clock)
Number of subjects: 100
Study: 32619497

Group type: EXPERIMENTAL
Intervention: Metformin prescription
Number of subjects: 526

Group type: COMPARATOR
Intervention: T2DM without metformin prescription
Number of subjects: 526

Group type: COMPARATOR
Intervention: Non-T2DM patients
Number of subjects: 526
Study: 36384562

Group type: EXPERIMENTAL
Intervention: Infliximab plus methotrexate (IFX + MTX)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Triple therapy (hydroxychloroquine, sulphasalazine, and methotrexate) (TRIPLE)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Methotrexate monotherapy (MTX)
Number of subjects: 60
Study: 33281442

Group type: EXPERIMENTAL
Intervention: XBJ
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 36129221

Group type: EXPERIMENTAL
Intervention: Patient Decision Aid (PDA)
Number of subjects: 105

Group type: COMPARATOR
Intervention: No Patient Decision Aid (Control)
Number of subjects: 105
Study: 33972448

Group type: EXPERIMENTAL
Intervention: Alcohol consumption during social interaction
Number of subjects: 20000

Group type: COMPARATOR
Intervention: No alcohol consumption (control)
Number of subjects: 20000
Study: 33172390

Group type: EXPERIMENTAL
Intervention: HCC with PVT
Number of subjects: 78
Study: 35704559

Group type: EXPERIMENTAL
Intervention: Azithromycin (AZM: 250mg), once-weekly weight-based dose of 1-5 tablets, taken orally.
Number of subjects: 347

Group type: COMPARATOR
Intervention: Placebo, taken orally.
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Azithromycin (AZM: 250mg)
Number of subjects: 347
Study: 34413300

Group type: EXPERIMENTAL
Intervention: Neoadjuvant immune checkpoint inhibitors (ICIs)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy
Number of subjects: 72
Study: 32571649

Group type: EXPERIMENTAL
Intervention: Low Level Laser Therapy (LLLT) with passive self-ligating brackets
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Low Level Laser Therapy (LLLT) with conventional brackets
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (conventional brackets without LLLT)
Number of subjects: 65
Study: 35817323

Group type: COMPARATOR
Intervention: 40 Gy/15 fractions/3 weeks (standard treatment)
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: 26 Gy/5 fractions/1 week (novel treatment)
Number of subjects: 271

Group type: COMPARATOR
Intervention: 8 Gy/15 fractions/3 weeks (control for simultaneous integrated boost)
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: 6 Gy/5 fractions/1 week (experimental for simultaneous integrated boost)
Number of subjects: 271

Group type: COMPARATOR
Intervention: 12 Gy/4 fractions/4 days (for sequential boost)
Number of subjects: 271
Study: 34172540

Group type: EXPERIMENTAL
Intervention: Workplace Active Rest Programme (WARP)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control (usual activities)
Number of subjects: 29
Study: 32224802

Group type: EXPERIMENTAL
Intervention: Pharmacological pupil dilatation
Number of subjects: 106
Study: 33797858

Group type: EXPERIMENTAL
Intervention: Art-training group (n = 43) attended four 1-hour sessions to solve technical drawing worksheets
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (n = 41)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Art-training group (n = 43)
Number of subjects: 84
Study: 34873925

Group type: EXPERIMENTAL
Intervention: Ticagrelor monotherapy after 3-month DAPT
Number of subjects: 3056

Group type: COMPARATOR
Intervention: Ticagrelor-based 12-month DAPT
Number of subjects: 3056
Study: 1987034936

Group type: EXPERIMENTAL
Intervention: human recombinant interferon-alpha
Number of subjects: 18
Study: 34343051

Group type: EXPERIMENTAL
Intervention: Tailored counselling intervention
Number of subjects: 192

Group type: COMPARATOR
Intervention: Conventional case management (Control)
Number of subjects: 192
Study: 34673895

Group type: EXPERIMENTAL
Intervention: 12 mg/d of intravenous dexamethasone
Number of subjects: 1000

Group type: COMPARATOR
Intervention: 6 mg/d of intravenous dexamethasone
Number of subjects: 1000
Study: 32372161

Group type: EXPERIMENTAL
Intervention: Hypertonic saline solution (5%) 4 times daily for 14 days
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Hypertonic saline solution (5%)
Number of subjects: 183
Study: 35486517

Group type: EXPERIMENTAL
Intervention: Dynamic augmented (DA) ACL suture repair (ACLSR)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Anatomic single-bundle ACL reconstruction (ACLR)
Number of subjects: 48
Study: 33910581

Group type: EXPERIMENTAL
Intervention: Body fat percentage (BF%)
Number of subjects: 100716
Study: 32540553

Group type: EXPERIMENTAL
Intervention: Trastuzumab (4 mg/kg, biweekly) plus oral capecitabine (1500 mg/daily) and cyclophosphamide (50 mg/daily)
Number of subjects: 60
Study: 35546102

Group type: EXPERIMENTAL
Intervention: Robot-assisted laparoscopic prostatectomy (RALP)
Number of subjects: 2672
Study: 33336844

Group type: EXPERIMENTAL
Intervention: FOLFOXIRI-bevacizumab
Number of subjects: 317

Group type: COMPARATOR
Intervention: FOLFOX-panitumumab
Number of subjects: 317
Study: 35279890

Group type: EXPERIMENTAL
Intervention: Brodalumab 210 mg every 2 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Brodalumab 210 mg after brodalumab 140 mg or placebo
Number of subjects: 0
Study: 34124244

Group type: EXPERIMENTAL
Intervention: Increased serum uric acid level
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low serum uric acid level
Number of subjects: 0

Group type: COMPARATOR
Intervention: Genetically determined uric acid levels
Number of subjects: 0
Study: 32367870

Group type: EXPERIMENTAL
Intervention: 600 μg oral misoprostol
Number of subjects: 100

Group type: COMPARATOR
Intervention: Manual vacuum aspiration (MVA)
Number of subjects: 100
Study: 35793047

Group type: EXPERIMENTAL
Intervention: Once-daily alogliptin/metformin combination tablet (alogliptin 25 mg/metformin 500 mg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Twice-daily anagliptin/metformin combination tablet low dose (anagliptin 100 mg/metformin 250 mg)
Number of subjects: 48
Study: 33342526

Group type: EXPERIMENTAL
Intervention: Packed Promise intervention (home-delivered food boxes with $38 food value and $15 check for fruits and vegetables)
Number of subjects: 4750

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 4750
Study: 33610420

Group type: EXPERIMENTAL
Intervention: Genetically predicted relative carbohydrate intake (E%)
Number of subjects: 268922

Group type: EXPERIMENTAL
Intervention: Genetically predicted dietary intake of fat (E%)
Number of subjects: 268922

Group type: EXPERIMENTAL
Intervention: Higher BMI
Number of subjects: 268922

Group type: EXPERIMENTAL
Intervention: Higher waist circumference
Number of subjects: 268922
Study: 35671902

Group type: EXPERIMENTAL
Intervention: Autism Eats intervention (n = 24)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Enhanced usual care (EUC) comparison group (n = 24)
Number of subjects: 48
Study: 32066254

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri CRL1324, Lactobacillus gasseri CRL1263 and CRL1307
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus CRL1332, L. gasseri CRL1256 and CRL1320
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study: 36353762

Group type: EXPERIMENTAL
Intervention: Amenamevir 1200 mg
Number of subjects: 605

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 605
Study: 34191244

Group type: EXPERIMENTAL
Intervention: Paxis Good Behavior Game (PaxGBG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intentional prevention initiatives promoting evidence-based practices
Number of subjects: 0
Study: 32717448

Group type: EXPERIMENTAL
Intervention: TTP block
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (fentanyl only)
Number of subjects: 80
Study: 35977732

Group type: EXPERIMENTAL
Intervention: SMART Work and Life (SWAL) intervention
Number of subjects: 756

Group type: EXPERIMENTAL
Intervention: SWAL intervention with a height adjustable desk (SWAL plus desk)
Number of subjects: 756

Group type: EXPERIMENTAL
Intervention: SWAL plus desk
Number of subjects: 756

Group type: COMPARATOR
Intervention: Control (usual practice)
Number of subjects: 756

Group type: EXPERIMENTAL
Intervention: Both intervention groups (SWAL and SWAL plus desk)
Number of subjects: 756
Study: 33218568

Group type: EXPERIMENTAL
Intervention: Mat Pilates
Number of subjects: 24
Study: 33685864

Group type: EXPERIMENTAL
Intervention: Etelcalcetide 5 mg thrice weekly
Number of subjects: 326

Group type: COMPARATOR
Intervention: Maxacalcitol 5 or 10 µg thrice weekly
Number of subjects: 326
Study: 32845519

Group type: EXPERIMENTAL
Intervention: 1% NVX‐207
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 1% BA
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 35452478

Group type: EXPERIMENTAL
Intervention: SMART intervention (two-hour workshop + optional 24-week online program)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 40
Study: 33727260

Group type: EXPERIMENTAL
Intervention: Androgen deprivation (AD)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Androgen deprivation + palbociclib (AD + palbociclib)
Number of subjects: 60
Study: 35812818

Group type: EXPERIMENTAL
Intervention: Immersive virtual reality experience during haemodialysis (4-week intervention period with 12 sessions)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual activities (control group during 4-week control period)
Number of subjects: 40
Study: 33761804

Group type: EXPERIMENTAL
Intervention: Open label once daily subcutaneous vosoritide combined with standard of care
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard of care alone
Number of subjects: 20
Study: 35276810

Group type: EXPERIMENTAL
Intervention: Ferrous bisglycinate (equiv. iron 24 mg) with folinic acid and multivitamins (test group, n = 60)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Ferrous fumarate (equiv. iron 66 mg, control group, n = 60)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Ferrous bisglycinate with folinic acid (test group)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Ferrous fumarate (control group)
Number of subjects: 120
Study: 34387246

Group type: EXPERIMENTAL
Intervention: Cognitive aid
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control
Number of subjects: 34
Study: 34952877

Group type: EXPERIMENTAL
Intervention: subacromial impingement syndrome
Number of subjects: 1308

Group type: EXPERIMENTAL
Intervention: rotator cuff tear
Number of subjects: 1308

Group type: EXPERIMENTAL
Intervention: bursitis
Number of subjects: 1308

Group type: EXPERIMENTAL
Intervention: shoulder sprain
Number of subjects: 1308

Group type: EXPERIMENTAL
Intervention: episode of shoulder pain
Number of subjects: 1308
Study: 32833549

Group type: EXPERIMENTAL
Intervention: Oral Nutritional Supplements (ONS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine Treatment (RT)
Number of subjects: 0
Study: 33063570

Group type: EXPERIMENTAL
Intervention: Enhanced Care (EC)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 134
Study: 35835435

Group type: EXPERIMENTAL
Intervention: Intact grafts (SCR or BG)
Number of subjects: 50
Study: 32109784

Group type: EXPERIMENTAL
Intervention: Matched sample from the sexual violence prevention program
Number of subjects: 10135

Group type: EXPERIMENTAL
Intervention: Students who complied with RCT protocol
Number of subjects: 10135

Group type: EXPERIMENTAL
Intervention: Students with a history of victimization or perpetration of sexual violence
Number of subjects: 10135
Study: 35503613

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (AE)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intermittent exercise (HIIT)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Resistance exercise (RE)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 120
Study: 33585959

Group type: EXPERIMENTAL
Intervention: Robotic RAMPS using the flip-up approach
Number of subjects: 0
Study: 34261052

Group type: EXPERIMENTAL
Intervention: Heated environment (HOT; ∼36 °C) during supine position (SUP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Heated environment (HOT; ∼36 °C) during orthostatic position (ORT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thermal reference (TC; ∼24 °C) during supine position (SUP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thermal reference (TC; ∼24 °C) during orthostatic position (ORT)
Number of subjects: 0
Study: 34865586

Group type: EXPERIMENTAL
Intervention: G100 20 µg/dose
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: G100 plus pembrolizumab
Number of subjects: 18
Study: 32662661

Group type: EXPERIMENTAL
Intervention: Surgical wound negative pressure drainage (Group 1)
Number of subjects: 1162

Group type: COMPARATOR
Intervention: No surgical wound drainage (Group 2)
Number of subjects: 1162

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1162
Study: 32303761

Group type: EXPERIMENTAL
Intervention: Opioid Agonist Therapy (OAT)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Non-OAT
Number of subjects: 124
Study: 35356068

Group type: EXPERIMENTAL
Intervention: Simvastatin combined with resistance training
Number of subjects: 111

Group type: COMPARATOR
Intervention: Simvastatin alone (Control Group)
Number of subjects: 111
Study: 34088702

Group type: EXPERIMENTAL
Intervention: 3-year lifestyle intervention
Number of subjects: 2184
Study: 33222584

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 3438

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3438
Study: 35303190

Group type: EXPERIMENTAL
Intervention: Telephone-Delivered Acceptance and Commitment Therapy (ACT) intervention for hazardous drinking
Number of subjects: 23
Study: 32757446

Group type: EXPERIMENTAL
Intervention: Intravenous Meloxicam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34609029

Group type: EXPERIMENTAL
Intervention: Crocin (30 mg, two tablets of 15 mg per day for 8 weeks)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44